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Dear Editor,
Proliferative idiopathic juxtafoveal retinal telangiectasia
(PIJRT) is characterized by bilateral ectatic lesions of the
perifoveal capillaries associated with subretinal neovascu-
larization (SRNV) [1], and has a poor natural history. [2]
It has been hypothesized that vascular endothelial
growth factor-A (VEGF-A) might play an important role
in the pathogenesis of PIJRT. [3] Ranibizumab (Lucentis®,
Genentech, South San Francisco, CA, USA) neutralizes all
active forms of VEGF-A, and has been found to be
effective in the treatment of exudative age-related macular
degeneration. However, as far as we are aware, this is the
first case to report efficacy of ranibizumab as monotherapy
in the treatment of PIJT.
A 56-year-old woman was admitted to our hospital with
progressive visual loss over 1 week in her right eye. Best-
corrected visual acuity (BCVA) at presentation was 0.2
(decimal equivalent). Fluorescein angiography (FFA)
showed dilated, ectatic capillaries involving the temporal
juxtafoveolar retina, with late exudation in both eyes and
evidence of active SRNV in the right eye (Fig. 1).
Optical coherence tomography (OCT) (Carl Zeiss Meditec,
Inc.) of both eyes revealed increased thickness of the temporal
parafoveal retina and foveal cystoid spaces. In the right eye,
OCT revealed a hyper-reflective lesion at inner retinal layers
on the temporal juxtafoveal retina corresponding to the SRNV
(Fig. 2).
Following informed written consent, ranibizumab (0.5 mg)
was administered intravitreally. The patient was followed
monthly with OCT and FFA. Reinjection criteria were
evidence of SRNVactivity on FFA.
One month after treatment, BCVA improved to 0.32
(decimal equivalent), and central macular thickness (CMT)
on OCT decreased. Exudation from both the SRNV and the
ectatic vessels was decreased but still persistent on FFA.
Two more injections at monthly intervals were adminis-
tered in order to obtain complete regression of the neovascular
complex.
At 4-month follow-up and after three injections at
monthly intervals, FFA revealed no activity of the SRNV.
BCVA improved to 0.5 (decimal equivalent). FFA showed
regression of the neovascular complex with absence of
exudation and, additionally, marked regression of the
ectatic dilatation of the parafoveal vessels (Fig. 1).
At 6-month follow-up, 2 months after the third injection,
BCVA decreased to 0.4 (decimal equivalent). OCT dem-
onstrated cystoid foveal cysts, and FFA showed leakage
from the ectatic vessels but no signs of SRNV activity
(Figs. 1 and 2). Patient was not re-treated, and BCVA, FFA
and OCT findings remained stable until the last follow-up
at 8 months.
PIJT has been reported to have a poor natural history,
with 80% of cases ending with a final visual acuity of 0.1
decimal equivalent or worse [2].
Several treatment modalities have been assessed [4, 5],
with poor results in most of the cases. Recently, several
studies have shown favorable functional and anatomic results
using the off-label anti-VEGF–A drug bevacizumab in the
treatment of PIJT [3, 6, 7]. In 2008, Rishi et al. reported a
case of PIJT that underwent primary treatment with a
combination of photodynamic therapy (PDT) and intravitreal
ranibizumab that demonstrated functional improvement [8].
Graefes Arch Clin Exp Ophthalmol (2009) 247:1567–1569
DOI 10.1007/s00417-009-1117-3
L. Konstantinidis : I. Mantel : L. Zografos :A. Ambresin (*)
Hôpital Ophtalmique Jules Gonin, University of Lausanne,
15 Av. de France,
CH-1004 Lausanne, Switzerland
e-mail: aude.ambresin@fa2.ch
Fig. 2 OCT findings (macular map and horizontal macular scan) of the
right eye at the baseline, at 4-month follow-up and at 6-month follow-up.
Baseline: OCT reveals increased thickness of the temporal parafoveal
retina and a foveal cystoid space. Note the hyper-reflective lesion at
inner retinal layers on the temporal juxtafoveal retina corresponding to
the SRNV. Four-month follow-up: OCT shows significant decrease of
CMT. Six-month follow-up: At 6-month follow-up, 2 months after the
third injection, OCT demonstrated increased CMT and small cystoid
foveal cysts
Fig. 1 Angiography findings of the left eye at baseline and the right eye
at baseline, at 4-month follow-up and at 6-month follow-up.Baseline (left
eye): FFA shows dilated, ectatic capillaries involving the temporal
juxtafoveolar retina with late exudation. Baseline (right eye): FFA
shows dilated, ectatic capillaries involving the temporal juxtafoveolar
retina with late exudation and evidence of active SRNV. Four-month
follow-up (right eye): FFA shows absence of exudation from SRNVand
additionally, marked regression of the ectatic dilatation of the parafoveal
vessels. Six-month follow-up (right eye): FFA shows leakage from the
ectatic vessels but no signs of SRNV activity
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In our case, treatment with three monthly interval
intravitreal injections of ranibizumab resulted in an im-
provement of BCVA and complete resolution of SRNV
during the follow-up period. However, effect of ranibizu-
mab on ectatic vessel activity seemed to be more transient
in this case. FFA appeared to be a very useful exam to
evaluate treatment efficacy to SRNV activity.
Ranibizumab may be an effective treatment of PIJT;
however, further studies are warranted to determine more
precisely its clinical benefit and its safety in the treatment of
PIJT.
Financial Support None
References
1. Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B
(2006) Idiopathic macular telangiectasia. Arch Ophthalmol 124:450–
460
2. Engelbrecht NE, Aaberg TM Jr, Sung J, Lewis ML (2002)
Neovascular membranes associated with idiopathic juxtafoveolar
telangiectasis. Arch Ophthalmol 120:320–324
3. Kovach JL, Rosenfeld PJ (2009) Bevacizumab (avastin) therapy for
idiopathic macular telangiectasia type II. Retina 29:27–32
4. Snyers B, Verougstraete C, Postelmans L, Leys A, Hykin P (2004)
Photodynamic therapy of subfoveal neovascular membrane in type
2a idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol
137:812–819
5. Berger AS, McCuen BW 2nd, Brown GC, Brownlow RL Jr (1997)
Surgical removal of subfoveal neovascularization in idiopathic
juxtafoveolar retinal telangiectasis. Retina 17:94–98
6. Jorge R, Costa RA, Calucci D, Scott IU (2007) Intravitreal
bevacizumab (avastin) associated with the regression of subretinal
neovascularization in idiopathic juxtafoveolar retinal telangiectasis.
Graefes Arch Clin Exp Ophthalmol 245:1045–1048
7. Mandal S, Venkatesh P, Abbas Z, Vohra R, Garg S (2007)
Intravitreal bevacizumab (avastin) for subretinal neovascularization
secondary to type 2a idiopathic juxtafoveal telangiectasia. Graefes
Arch Clin Exp Ophthalmol 245:1825–1829
8. Rishi P, Shroff D, Rishi E (2008) Combined photodynamic therapy
and intravitreal ranibizumab as primary treatment for subretinal
neovascular membrane (srnvm) associated with type 2 idiopathic
macular telangiectasia. Graefes Arch Clin Exp Ophthalmol
246:619–621
Graefes Arch Clin Exp Ophthalmol (2009) 247:1567–1569 1569
